JP2018522041A5 - - Google Patents

Download PDF

Info

Publication number
JP2018522041A5
JP2018522041A5 JP2018505476A JP2018505476A JP2018522041A5 JP 2018522041 A5 JP2018522041 A5 JP 2018522041A5 JP 2018505476 A JP2018505476 A JP 2018505476A JP 2018505476 A JP2018505476 A JP 2018505476A JP 2018522041 A5 JP2018522041 A5 JP 2018522041A5
Authority
JP
Japan
Prior art keywords
brachyury
yeast
immunotherapy composition
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018505476A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018522041A (ja
JP6789283B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/044977 external-priority patent/WO2017023840A1/en
Publication of JP2018522041A publication Critical patent/JP2018522041A/ja
Publication of JP2018522041A5 publication Critical patent/JP2018522041A5/ja
Application granted granted Critical
Publication of JP6789283B2 publication Critical patent/JP6789283B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018505476A 2015-08-03 2016-08-01 改変酵母−ブラキュリー免疫療法組成物 Active JP6789283B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562200497P 2015-08-03 2015-08-03
US62/200,497 2015-08-03
PCT/US2016/044977 WO2017023840A1 (en) 2015-08-03 2016-08-01 Modified yeast-brachyury immunotherapeutic compositions

Publications (3)

Publication Number Publication Date
JP2018522041A JP2018522041A (ja) 2018-08-09
JP2018522041A5 true JP2018522041A5 (enExample) 2019-09-12
JP6789283B2 JP6789283B2 (ja) 2020-11-25

Family

ID=56618277

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018505476A Active JP6789283B2 (ja) 2015-08-03 2016-08-01 改変酵母−ブラキュリー免疫療法組成物

Country Status (11)

Country Link
US (1) US11065313B2 (enExample)
EP (1) EP3331552B1 (enExample)
JP (1) JP6789283B2 (enExample)
KR (1) KR102833272B1 (enExample)
CN (1) CN108348586B (enExample)
AU (1) AU2016303525B2 (enExample)
CA (1) CA2994272C (enExample)
HK (1) HK1249431A1 (enExample)
IL (1) IL257208B (enExample)
TW (1) TWI748957B (enExample)
WO (1) WO2017023840A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX374829B (es) 2013-03-19 2025-03-06 Globeimmune Inc Composición a base de levadura para usarse para tratar cordoma.
CA2948803A1 (en) * 2014-04-11 2015-10-15 Globeimmune, Inc. Yeast-based immunotherapy and type i interferon sensitivity
JP7048482B2 (ja) 2015-08-03 2022-04-05 アメリカ合衆国 Brachyury欠失変異体、Brachyury欠失変異体をコードする非酵母ベクター、及びそれらの使用
CN119818663A (zh) * 2018-05-15 2025-04-15 全球免疫公司 用于诱导细胞免疫应答的重组酵母裂解物
KR20210094609A (ko) 2018-11-28 2021-07-29 포티 세븐, 인코포레이티드 절제 레짐에 대해 저항성인 유전적으로 변형된 hspc
WO2022187963A1 (en) * 2021-03-10 2022-09-15 Provincial Health Services Authority Immunotherapy agents targeting brachyury and methods of using same
EP4489774A4 (en) * 2022-03-08 2026-04-29 Immunitybio Inc YEAST-BASED VACCINE INJECTED INTRATUMORALLY
EP4516807A1 (en) 2023-08-28 2025-03-05 Consorcio Centro de Investigación Biomédica en Red Compositions for use in a method of providing improved hematopoietic stem cell engraftment

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2486400B1 (fr) 1980-07-09 1986-05-30 Univablot Medicaments a base de levures ou de leurs extraits insolubles
NZ199722A (en) 1981-02-25 1985-12-13 Genentech Inc Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain
US4775622A (en) 1982-03-08 1988-10-04 Genentech, Inc. Expression, processing and secretion of heterologous protein by yeast
US5310654A (en) 1985-07-31 1994-05-10 The Board Of Trustees Of The Leland Stanford Junior University Method for determining virulence of Yersinia
US5234830A (en) 1988-02-03 1993-08-10 Suntory Limited DNA encoding a KEX2 endoprotease without a C-terminal hydrophobic region
IL95019A0 (en) 1989-08-09 1991-06-10 Mycogen Corp Process for encapsulation of biologicals
US5830463A (en) 1993-07-07 1998-11-03 University Technology Corporation Yeast-based delivery vehicles
US5413914A (en) 1993-07-07 1995-05-09 The Regents Of The University Of Colorado Yeast assay to identify inhibitors of dibasic amino acid processing endoproteases
US5858378A (en) 1996-05-02 1999-01-12 Galagen, Inc. Pharmaceutical composition comprising cryptosporidium parvum oocysts antigen and whole cell candida species antigen
AU9589398A (en) 1997-10-10 1999-05-03 Applied Immunotherapeutics, Inc. Cancer immunotherapy using allostimulated cells in a multiple sequential implantation strategy
US5948646A (en) 1997-12-11 1999-09-07 Fordham University Methods for preparation of vaccines against cancer comprising heat shock protein-peptide complexes
US20020044948A1 (en) 2000-03-15 2002-04-18 Samir Khleif Methods and compositions for co-stimulation of immunological responses to peptide antigens
EP1272213B1 (en) 2000-04-06 2006-03-08 SEER Pharmaceuticals, LLC. Microbial delivery system
AU2002225681A1 (en) 2000-11-15 2002-05-27 Globe Immune, Inc. Yeast-dentritic cell vaccines and uses thereof
JP4914990B2 (ja) 2002-12-16 2012-04-11 グローブイミューン,インコーポレイテッド 動物を癌から守るための治療用組成物
US7439042B2 (en) 2002-12-16 2008-10-21 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
US20060009404A1 (en) 2004-07-09 2006-01-12 Williams Jason R Tumor ablation in combination with pharmaceutical compositions
WO2007008780A2 (en) 2005-07-11 2007-01-18 Globeimmune, Inc. Compositions and methods for eliciting an immune response to escape mutants of targeted therapies
US20070172503A1 (en) 2005-12-13 2007-07-26 Mycologics,Inc. Compositions and Methods to Elicit Immune Responses Against Pathogenic Organisms Using Yeast Based Vaccines
CA2638815A1 (en) 2006-02-02 2007-08-16 Globeimmune, Inc. Yeast-based vaccine for inducing an immune response
TW200806789A (en) 2006-03-27 2008-02-01 Globeimmune Inc RAS mutation and compositions and methods related thereto
CN101687030B (zh) 2007-02-02 2014-07-02 环球免疫公司 用于生产基于酵母的疫苗的方法
CA2678404C (en) * 2007-02-28 2019-03-19 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Brachyury polypeptides and methods for use
WO2008115610A1 (en) 2007-03-19 2008-09-25 Globeimmune, Inc. Compositions and methods for targeted ablation of mutational escape of targeted therapies for cancer
WO2009042642A2 (en) * 2007-09-24 2009-04-02 President And Fellows Of Harvard College Compositions and methods for the treatment and prevention of ulcerative colitis and colon cancer
EP2331125A4 (en) 2008-09-19 2013-03-27 Globeimmune Inc IMMUNOTHERAPY FOR CHRONIC HEPATITIS C-VIRUS INFECTIONS
WO2010065626A1 (en) 2008-12-02 2010-06-10 Globeimmune, Inc. Genotyping tools, methods and kits
ES2660597T3 (es) * 2009-04-17 2018-03-23 Globeimmune, Inc. Composiciones inmunoterápicas de combinación contra el cáncer y métodos
US8911722B2 (en) 2009-09-14 2014-12-16 The Regents Of The University Of Colorado, A Body Corporate Modulation of yeast-based immunotherapy products and responses
US20130121964A1 (en) 2010-03-14 2013-05-16 Globeimmune, Inc. Pharmacogenomic and Response-Guided Treatment of Infectious Disease Using Yeast-Based Immunotherapy
GB201004575D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers
WO2012019127A2 (en) 2010-08-05 2012-02-09 The Regents Of The University Of Colorado Combination yeast-based immunotherapy and arginine therapy for the treatment of myeloid-derived supressor cell-associated diseases
EP2651439B1 (en) 2010-12-17 2018-09-19 Globeimmune, Inc. Compositions and methods for the treatment or prevention of human adenovirus-36 infection
PE20140844A1 (es) 2011-02-12 2014-07-14 Globeimmune Inc Terapeuticos a base de levadura para infeccion de la hepatitis b cronica
JP6068368B2 (ja) 2011-03-17 2017-01-25 グローブイミューン,インコーポレイテッド 酵母−ブラキュリ免疫治療組成物
EP2720716B1 (en) 2011-06-14 2018-03-21 Globeimmune, Inc. Immunotherapeutic compositions for the treatment or prevention of hepatitis delta virus infection
CN109010809A (zh) 2011-08-17 2018-12-18 全球免疫股份有限公司 酵母-muc1免疫治疗组合物及其用途
MX374829B (es) 2013-03-19 2025-03-06 Globeimmune Inc Composición a base de levadura para usarse para tratar cordoma.

Similar Documents

Publication Publication Date Title
Zuo et al. An engineered oncolytic vaccinia virus encoding a single-chain variable fragment against TIGIT induces effective antitumor immunity and synergizes with PD-1 or LAG-3 blockade
TWI704226B (zh) 重組溶瘤病毒組合物及其用途
JP7564572B2 (ja) 単離された組換え体腫瘍溶解性ワクシニアウイルスとnk細胞を含む治療薬、その使用およびそれを適用したキット
Francis et al. Modulation of chemokines in the tumor microenvironment enhances oncolytic virotherapy for colorectal cancer
JP2014509595A5 (enExample)
JP2021518414A5 (enExample)
RU2015103758A (ru) Днк-вакцина для применения у пациентов с раком поджелудочной железы
RU2019132253A (ru) Новая днк-вакцина, нацеленная на pd-l1, для иммунотерапии рака
Shi et al. An oncolytic vaccinia virus armed with anti-human-PD-1 antibody and anti-human-4-1BB antibody double genes for cancer-targeted therapy
CN105031630A (zh) 同时分泌pd-1中和抗体和gm-csf因子的肿瘤细胞疫苗及其制备方法
CN108261426A (zh) 药物组合物及其在治疗肿瘤和/或癌症的药物中的应用
IL257208A (en) Brachyury-modified immunotherapeutic preparations
JP2014139185A5 (enExample)
JP2020511139A5 (enExample)
Molinelli et al. Biologic therapy in psoriasis (Part II): efficacy and safety of new treatment targeting IL23/IL-17 pathways
CN105462975A (zh) 一种特异性抑制ctgf基因表达的小干扰rna及其应用
JP2015000064A5 (enExample)
Xue et al. Anti-tumour research of recombinant BCG using BZLF1 and hGM-CSF fusion genes
CN113425856B (zh) 一种含有基因修饰的溶瘤病毒的药物组合物及其在治疗癌症的用途
CN101050470A (zh) 携带c57bl/6鼠端粒酶逆转录酶的重组腺病毒载体
WO2018201602A1 (zh) 重组溶瘤ii型单纯疱疹病毒在制备抗淋巴瘤、食道癌、乳腺癌、胰腺癌药物中的应用
Iyer et al. Molecular insights and promise of oncolytic virus based immunotherapy
CN105462976A (zh) 一种特异性抑制twist1基因表达的小干扰rna及其应用
KR20220079799A (ko) 예방접종 및 질환 요법을 위한 자가유래 유도 만능 줄기 세포와의 폭스바이러스의 용도
Alshareef et al. MEDU-23. IMPROVING IMMUNOTHERAPEUTIC POTENTIAL IN GROUP 3 MEDULLOBLASTOMA USING LOW DOSE RADIATION FOLLOWED BY 4-1BB MONOCLONAL ANTIBODY ADMINISTRATION